IRIS UniCatt

Orlandi, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.281
AS - Asia 3.548
EU - Europa 2.695
SA - Sud America 828
AF - Africa 136
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.142
SG - Singapore 1.507
BR - Brasile 687
CN - Cina 643
VN - Vietnam 631
DE - Germania 628
SE - Svezia 456
IT - Italia 436
FR - Francia 270
IN - India 184
GB - Regno Unito 158
PL - Polonia 134
FI - Finlandia 131
IE - Irlanda 130
ID - Indonesia 102
HK - Hong Kong 92
JP - Giappone 85
RU - Federazione Russa 80
BD - Bangladesh 67
AR - Argentina 64
CA - Canada 61
UA - Ucraina 57
MX - Messico 56
TR - Turchia 41
ES - Italia 40
CI - Costa d'Avorio 38
ZA - Sudafrica 33
IQ - Iraq 32
AT - Austria 30
KR - Corea 29
NL - Olanda 29
EC - Ecuador 26
BE - Belgio 19
CO - Colombia 18
IR - Iran 18
SA - Arabia Saudita 18
MA - Marocco 17
LT - Lituania 15
PK - Pakistan 14
RO - Romania 14
CZ - Repubblica Ceca 11
PH - Filippine 11
CH - Svizzera 10
UZ - Uzbekistan 10
VE - Venezuela 10
CL - Cile 9
TN - Tunisia 9
AU - Australia 8
EG - Egitto 8
NP - Nepal 8
RS - Serbia 8
IL - Israele 7
KE - Kenya 7
MY - Malesia 7
LB - Libano 6
LU - Lussemburgo 6
DZ - Algeria 5
HU - Ungheria 5
JO - Giordania 5
KZ - Kazakistan 5
PY - Paraguay 5
SN - Senegal 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BO - Bolivia 4
JM - Giamaica 4
NO - Norvegia 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CR - Costa Rica 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
LV - Lettonia 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BY - Bielorussia 2
CG - Congo 2
EU - Europa 2
GA - Gabon 2
GR - Grecia 2
KW - Kuwait 2
MU - Mauritius 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
SV - El Salvador 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CD - Congo 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GT - Guatemala 1
Totale 11.487
Salva come PNG Salva come JPEG
Città #
Singapore 851
Chandler 487
San Jose 467
Ashburn 446
Ho Chi Minh City 199
Hanoi 168
Beijing 139
New York 138
Chicago 127
Los Angeles 127
Dublin 123
Warsaw 122
Council Bluffs 110
Rome 109
Lauterbourg 101
Munich 95
Hyderabad 89
Hefei 87
The Dalles 80
Fairfield 78
Houston 75
Tokyo 75
Hong Kong 74
Jakarta 74
Wilmington 73
Milan 71
São Paulo 70
Frankfurt am Main 65
San Mateo 64
Boston 55
Helsinki 50
Ann Arbor 48
Princeton 47
Woodbridge 47
Turku 46
Moscow 43
Nanjing 40
London 39
Abidjan 38
Seattle 37
Cattolica 34
Jacksonville 34
Cambridge 33
Orem 33
Buffalo 31
Da Nang 30
Dallas 30
St Louis 30
Dearborn 29
Paris 29
Haiphong 28
Kent 28
Redwood City 28
Marseille 26
Nuremberg 26
Santa Clara 26
Seoul 26
Chennai 25
Izmir 22
Lappeenranta 22
Nürnberg 21
Salt Lake City 21
Montreal 20
Toronto 20
Brooklyn 18
Düsseldorf 18
Rio de Janeiro 18
Brussels 17
Mexico City 17
Phoenix 17
Bremen 16
Dhaka 16
Poplar 16
Stockholm 16
Boardman 15
Denver 15
Johannesburg 15
Manchester 15
Tampa 15
Amsterdam 14
Bari 14
Biên Hòa 14
Nanchang 14
Porto Alegre 14
Can Tho 13
Hangzhou 13
Guangzhou 12
Lancaster 12
Lawrence 12
Querétaro 12
Salvador 12
San Francisco 12
Vienna 12
Baghdad 11
Curitiba 11
Elk Grove Village 11
Hải Dương 11
Madrid 11
Mumbai 11
Shanghai 11
Totale 6.427
Salva come PNG Salva come JPEG
Nome #
Neoadjuvant chemotherapy in breast cancer: An advanced personalized multidisciplinary prehabilitation model (apmp-m) to optimize outcomes 307
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 306
Diagnosis and management of breast lymphoma: A single-institution retrospective analysis 267
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 234
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 226
Diagnosis and treatment of bone metastases in breast cancer: Radiotherapy, local approach and systemic therapy in a guide for clinicians 220
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 197
Mastectomy in precision oncology era: Myth or reality? 191
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 184
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 182
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 163
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 162
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 160
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis 159
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 159
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 156
AMAROS Study: Overall Survival in Breast Cancer Subtypes 154
Immediate prosthetic breast reconstruction after nipple-sparing mastectomy: Traditional subpectoral technique versus direct-to-implant prepectoral reconstruction without acellular dermal matrix 151
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: Preliminary experience with clinically node negative patients after systemic treatment 150
Clinical, pathological and prognostic features of rare braf mutations in metastatic colorectal cancer (Mcrc): A bi-institutional retrospective analysis (rebus study) 150
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients 149
191P Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis 149
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 145
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 145
Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies 145
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 144
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 143
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 140
Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis 139
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 137
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy 134
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 132
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 130
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 130
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2 124
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial 124
Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting 122
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria 120
OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer 120
Paradox CA 15-3 increase in metastatic breast cancer patients treated with everolimus: A change of paradigm in a case series 118
Characteristics and risk factors for SARS-CoV-2 in children tested in the early phase of the pandemic: a cross-sectional study, Italy, 23 February to 24 May 2020 118
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analisys 118
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 117
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 117
Usefulness of automated breast volume scanner (ABVS) for monitoring tumor response to neoadjuvant treatment in breast cancer patients: preliminary results 116
Menopausal hormone therapy: What should be kept in mind for a personalized choice in a shared decision-making 116
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis 115
Diffuse liver infiltration by lobular breast carcinoma: Shear wave elastography as gold standard imaging study. 114
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors 114
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials 112
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study 111
Baseline 18F-FDG PET/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters 111
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 111
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 108
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 106
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 104
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience 101
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives 100
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis 100
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study 98
LUX-Lung 7: is there enough data for a final conclusion? 98
Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort 97
Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes 97
Impact on survival of primary tumor resection in patients with metastatic breast cancer: preliminary results of a retrospective analysis 95
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA 94
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors 93
Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy 93
Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience 93
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope 92
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 90
From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective 87
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response 87
How will artificial intelligence impact breast cancer research efficiency? 86
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 86
Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians 85
The interference between oxaliplatin & anti-EGFR therapies: A different hypothesis to explain the 'unexplainable' 83
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 80
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature 80
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study 76
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 76
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 75
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 74
Definition of a tool to assess shared decision-making (SDM) on women with breast cancer: A value-based approach 73
Targeted therapy in advanced gastric carcinoma: The future is beginning 73
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer 69
New life for retrospective study in the precision oncology era 67
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 64
New challenges in multimodal workout of locally advanced breast cancer 62
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 61
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 59
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence 58
Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions 56
Automated breast volume scanner (ABVS) compared to handheld ultrasound (HHUS) and contrast-enhanced magnetic resonance imaging (CE-MRI) in the early assessment of breast cancer during neoadjuvant chemotherapy: an emerging role to monitoring tumor response? 53
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 53
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial 49
To treat or no to treat: HER2 equivocal is the matter! 47
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 45
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 44
Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx 42
BRAF in metastatic colorectal cancer: the future starts now 22
Totale 11.689
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.693
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202171 0 0 0 0 0 0 0 0 0 0 49 22
2021/2022657 59 11 10 67 18 50 18 83 34 41 131 135
2022/20231.395 188 194 99 197 79 142 90 135 145 40 52 34
2023/2024748 40 164 30 34 38 151 53 43 16 19 75 85
2024/20252.005 37 28 135 59 134 51 69 57 203 312 540 380
2025/20265.559 738 265 428 901 867 255 1.027 273 375 409 21 0
Totale 11.689